Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05054543 |
|
Recruitment Status :
Recruiting
First Posted : September 23, 2021
Last Update Posted : November 24, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Relapsed/Refractory AML | Drug: Uproleselan Drug: Placebo | Phase 3 |
This trial will enroll approximately 140 randomized subjects 18 through 75 years of age at the time of randomization with primary refractory AML or relapsed AML (first or second untreated relapse) and eligible to receive induction chemotherapy as described.
Randomization will be done at trial entry at a 1:1 ratio, and will be stratified by age (<60, ≥60 years) and disease status (primary refractory/early relapse ≤6 months, late relapse>6 months) and prior HSCT status. Treatment assignment received at randomization will be maintained during all induction and consolidation cycles.
This trial will have the following sequential phases: screening, baseline, induction treatment and count recovery, response assessment, consolidation treatment (if remission is achieved), and follow-up for relapse and survival assessment. Subjects not achieving remission will continue to be followed for long-term trial endpoints such as disease progression and survival. Blinding will be maintained until database lock. All subjects will be followed for long-term outcomes until death or withdrawal of consent.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 140 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Intervention Model Description: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 3 Randomized, Double-Blinded Bridging Trial to Evaluate the Efficacy of Uproleselan Administered With Chemotherapy Versus Chemotherapy Alone in Chinese Patients With Relapsed/Refractory Acute Myeloid Leukemia |
| Actual Study Start Date : | October 18, 2021 |
| Estimated Primary Completion Date : | October 2023 |
| Estimated Study Completion Date : | February 2024 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Uproleselan
Uproleselan in combination with mitoxantrone, etoposide and cytarabine (MEC) during induction; Uproleselan in combination with HiDAC/IDAC during consolidation
|
Drug: Uproleselan
A rationally designed E-selectin antagonist used to inhibit binding of cells to E-selectin
Other Name: GMI-1271 |
|
Placebo Comparator: Placebo (Saline, 0.9% Sodium Chloride)
Placebo in combination with mitoxantrone, etoposide and cytarabine (MEC) during induction; Placebo in combination with HiDAC/IDAC during consolidation
|
Drug: Placebo
0.9% Sodium Chloride
Other Name: Saline |
- Overall survival [ Time Frame: 3 years ]Time from the date of randomization into the study to the date of death.
- Remission rate(rate of CR, CR/CRi and CR/CRh) [ Time Frame: Up to 60 days ]Defined as the rate of subjects who reach CR, CR/CRi and CR/CRh
- Duration of remission [ Time Frame: Up to 3 years ]Time from date of first documented remission to date of relapse or death from any cause, whichever occurs first.
- Event-free survival [ Time Frame: Up to 3 years ]Time from date of randomization into the study to the date of treatment failure, relapse, or death from any cause; whichever occurs first.
- Rate of severe oral mucositis [ Time Frame: Up to 254 days ]Incidence of severe oral mucositis experienced in patients after treatment.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- ≥18 years and ≤75 years in age
- AML diagnosed with ≥20% myeloid marrow blasts or peripheral blood blasts per WHO criteria(2008) at the time of initial diagnosis
-
For refractory AML, only cytarabine/daunorubicin(or Idarubicin) as can be applied repeatedly(maximal twice) as induction, no other chemotherapy are allowed to be applied Venatoclax /hypomethylation drug [HMA] can be used before and after chemotherapy.
- For relapse AML, it must be the first or second relapse, and remain untreated.
- Certain regimens (Venatoclax/HMA, Venetoclax/LDAC, HMA single agent) and FLT3 inhibitors, tyrosine kinase inhibitors, IDH1/IDH2 inhibitors or similar targeted inhibitors used alone are not considered cytotoxic chemotherapy are allowed.
- No more than one prior stem cell transplant
- Has not received the chemotherapy regimen to be used for induction on this trial
- Is considered medically eligible to receive the chemotherapy regimen to be used for induction on this trial
Exclusion Criteria:
- Patients with acute promyelocytic leukemia
- Acute leukemia of ambiguous lineage (biphenotypic leukemia)
- Chronic myeloid leukemia with myeloid blast crisis
- Active signs or symptoms of CNS involvement by malignancy (No lumbar puncture required)
- Prior use of G-CSF, CM-CSF or plerixafor within 7 days of dosing.
- Stem cell transplantation ≤4 months prior to dosing.
- Any immunotherapy or radiotherapy therapy within 28 days of dosing; any other experimental therapy or chemotherapy within 14 days of dosing
- Inadequate organ function.
- Abnormal liver function.
- Known active infection with hepatitis A, B, or C, or human immunodeficiency virus.
- Moderate kidney dysfunction (glomerular filtration rate <45 mL/min).
- Uncontrolled acute life-threatening bacterial, viral, or fungal infection.
- Clinically significant cardiovascular disease.
- Major surgery within 4 weeks of dosing.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05054543
| Contact: Zhejiang CrownMab Ltd. | 0571-83521933 | ClinicalTrialsChina@apollomicsinc.com | |
| Contact: Qian Li | 0571-83521933 | Qian.Li@apollomicsinc.com |
| China, Tianjin | |
| Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College | Recruiting |
| Tianjin, Tianjin, China, 300020 | |
| Contact: Jianxiang Wang, Phd 022-23909120 wangjx@medmail.com.cn | |
| China | |
| The First Affiliated Hospital of Zhejiang University | Recruiting |
| Hangzhou, China | |
| Contact: Jie Jin, PhD 057187236685 jiej0503@zju.edu.cn | |
| Principal Investigator: | Jianxiang Wang, PhD | Institute of Hematology and Blood Diseases Hospital |
| Responsible Party: | Apollomics Inc. |
| ClinicalTrials.gov Identifier: | NCT05054543 |
| Other Study ID Numbers: |
APL-106-02 |
| First Posted: | September 23, 2021 Key Record Dates |
| Last Update Posted: | November 24, 2021 |
| Last Verified: | September 2021 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
AML |